Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination - PubMed (original) (raw)

Clinical Trial

. 1999 Aug 15;163(4):2249-55.

T Goetghebuer, M O Ota, I Wolfe, S J Ceesay, D De Groote, T Corrah, S Bennett, J Wheeler, K Huygen, P Aaby, K P McAdam, M J Newport

Affiliations

Clinical Trial

Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination

A Marchant et al. J Immunol. 1999.

Abstract

Data obtained in animals indicate that neonatal immune responses are biased toward Th2. This could reduce the efficacy of vaccines against viral and mycobacterial diseases. The ability of human newborns to develop a Th1 immune response upon immunization has not been studied. Since the vaccine Mycobacterium bovis bacillus Calmette-Guérin (BCG) triggers a Th1-type response in adults, we investigated whether it induces a similar response in newborns and whether age at vaccination influences immunogenicity. We found that BCG vaccination at birth induces a memory Th1-type response of similar magnitude to that when given later in life. This study demonstrates that human newborns can be immunized against pathogens controlled by a Th1 immune response.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources